Since the 12-month-old 3xTg-AD mice are reported to show both Aβ and tau pathologies [45,46,48,50], we rationalized that the assessment of both LTP and LTD at this age will be needed to completely understand the therapeutic potential of PLD1 chronic inhibition. This evidence concerns the gene MAPT and Alzheimer disease.